The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy von Holmström, M O, Martinenaite, E, Ahmad, S M, Met, Ö, Friese, C, Kjær, L, Riley, C H, thor Straten, P, Svane, I M, Hasselbalch, H C, Andersen, M H

Volltext

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms von Holmström, M O, Hjortsø, M D, Ahmad, S M, Met, Ö, Martinenaite, E, Riley, C, Straten, P, Svane, I M, Hasselbalch, H C, Andersen, M H

Volltext

Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications von Kiel Rasmussen, AC, Hulen, T.M., Petersen, D.L., Jacobsen, M.J., Mikkelsen, M.J., Met, Ö., Donia, M., Chamberlain, C.A., Mouritzen, P.

Volltext

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression von Andersen, R., Borch, T.H., Draghi, A., Gokuldass, A., Rana, M.A.H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J.W., Westergaard, M.C.W., Radic, H.D., Chamberlain, C.A., Hölmich, L.R., Hendel, H.W., Larsen, M.S., Met, Ö, Svane, I.M., Donia, M.

Volltext

Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin‐Expressing Cells von Nitschke, N. J., Bjoern, J., Met, O., Svane, I. M., Andersen, M. H.

Volltext

LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial von Haanen, J.B.A.G., Rohaan, M., Borch, T.H., van den Berg, J.H., Met, Ö., Foppen, M. Geukes, Granhøj, J. Stoltenborg, Nuijen, B., Nijenhuis, C., Beijnen, J.H., Jedema, I., van Zon, M., Noringriis, I. Mansfield, Kessels, R., Wilgenhof, S., van Thienen, H.V., Lalezari, F., van Akkooi, A.C.J., Donia, M., Svane, I-M.

Volltext

Dendritic cell vaccination in combination with docetaxel for patients with prostate cancer – a randomized phase II study von Kongsted, P., Ellebæk, E., Borch, T.H., Iversen, T.Z., Andersen, R., Met, Ö, Hansen, M., Sengeløv, L., Svane, I.M.

Volltext

T cell responses in the microenvironment of primary renal cell carcinoma von Andersen, R., Westergaard, M.C.W., Kjeldsen, J.W., Met, Ö, Kromann-Andersen, B., Hasselager, T., Donia, M., Svane, I.M.

Volltext

T-cell therapy in combination with vemurafenib in BRAF mutated metastatic melanoma patients von Borch, T.H., Andersen, R., Rana, M.A.H., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J.W., Kverneland, A., Met, Ö, Donia, M., Svane, I.M.

Volltext

T cell recognition of breast cancer antigens von Ramskov, S., Petersen, N Viborg, Sick Andersen, R., Straten, P Thor, Svane, I-M, Met, Ö, Hadrup, S Reker

Volltext

Adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic ovarian cancer: A pilot study von Pedersen, M., Westergaard, M., Nielsen, M., Borch, T.H., Poulsen, L.G., Hendel, H., Juhler-Nøttrup, T., Met, Ö., Donia, M., Svane, I-M.

Volltext

1132PDClinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients von Borch, T H, Andersen, R, Rana, M A H, Kongsted, P, Pedersen, M, Nielsen, M, Kjeldsen, J W, Kverneland, A, Lorentzen, C L, Met, Ö, Donia, M, Svane, I M

Volltext

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients von Borch, T.H., Andersen, R., Rana, M.A.H., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J.W., Kverneland, A., Lorentzen, C.L., Met, Ö, Donia, M., Svane, I.M.

Volltext

57P Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL) von Granhøj, J. Stoltenborg, Borch, T.H., Rohaan, M., Madsen, K., Jedema, I., Nijenhuis, C., van Zon, M., Nuijen, B., Van Houdt, W., Hölmich, L. Rosenkrantz, Met, Ö., Donia, M., Haanen, J.B.A.G., Svane, I-M.

Volltext

T cell responses in patients with melanoma resistant to multiple immunotherapies von Andersen, R., Borch, T.H., Draghi, A., Gokuldass, A., Rana, M.A.H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J.W., Westergaard, M.C.W., Hölmich, L.R., Hendel, H.W., Larsen, M.S., Met, Ö, Svane, I.M., Donia, M.

Volltext

The calreticulin von Riley, C H, Kjaer, L, Holmström, M O, thor Straten, P, Friese, C, Ahmad, S M, Hasselbalch, H C, Martinenaite, E, Svane, I M, Andersen, M H, Met, Ö

Volltext

1303TiPRandomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine... von Rohaan, M W, Borch, T H, van den Berg, J H, Geukes Foppen, M H, Donia, M, Met, Ö, Nuijen, B, van Zon, M, Bakker, E A M, de Boer, R, Pronk, L M, Wilgenhof, S, Blank, C U, van Thienen, J V, van Akkooi, A C J, Svane, I-M, Haanen, J B A G

Volltext

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to s... von Rohaan, M.W., Borch, T.H., van den Berg, J.H., Geukes Foppen, M.H., Donia, M., Met, Ö, Nuijen, B., van Zon, M., Bakker, E.A.M., de Boer, R., Pronk, L.M., Wilgenhof, S., Blank, C.U., van Thienen, J.V., van Akkooi, A.C.J., Svane, I.-M., Haanen, J.B.A.G.

Volltext

36MO Location and size of metastasectomy in melanoma patients treated with tumor-infiltrating lymphocytes (TIL) in relation to clinical outcome von Rohaan, M., Holz Borch, T., Kessels, R., Nijenhuis, C., van den Berg, J.H., Nuijen, B., Jedema, I., van Zon, M., Geukes Foppen, M., Torres Acosta, A., Wilgenhof, S., Lalezari, F., Rosenkrantz Hölmich, L., Van Houdt, W., Wouters, M., van Akkooi, A.C.J., Met, Ö., Donia, M., Svane, I-M., Haanen, J.B.A.G.

Volltext

PS1380 PEPTIDE VACCINATION AGAINST PD‐L1 (IO103) IN MULTIPLE MYELOMA – A PHASE I FIRST IN HUMAN TRIAL von Jørgensen, N.G., Ahmad, S.M., Klausen, U., Grauslund, J.H., Hansen, M., Martinenaite, E., Met, Ö., Svane, I.M., Knudsen, L.M., Andersen, M.H.

Volltext